Related Experiment Video
Updated: Jan 10, 2026
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
A bibliometric visualization of resistance to lung cancer immunotherapy: a decade of research progress (2014-2024)
Zhuo Yang1, Lanlan Yang1, Yuli Wang1
1Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Background:
Lung cancer remains the leading cause of cancer-related deaths globally and represents the most common malignant tumor. While immunotherapy has significantly improved patient survival in recent years, the development of resistance limits its clinical efficacy. Currently, a systematic and comprehensive bibliometric analysis of drug resistance in immunotherapy for lung cancer is lacking. This study aims to address this gap by employing bibliometric methods to illuminate the knowledge structure and to identify key research hotspots in this critical area.
Methods:
We retrieved publications concerning lung cancer immunotherapy drug resistance from the Web of Science Core Collection and PubMed databases, covering January 1, 2014, to December 31, 2024. NoteExpress was used for data integration, duplicate detection, and screening. Subsequently, we quantitatively and visually analyzed the characteristics of the selected literature, with an emphasis on country, institution, and keywords. This analysis was performed utilizing VOSviewer, CiteSpace, and the "bibliometrix" package in R.
Result:
The annual publication output showed a marked upward trend, peaking in 2024. China produced the most publications, while the USA demonstrated higher citation impact. Analysis of keywords revealed a clear thematic evolution: from initial focus on clinical trials (e.g. Open-label) and specific drugs (e.g. Nivolumab), to immune checkpoints (e.g.PD-1/PD-L1), and more recently to underlying molecular mechanisms like the tumor microenvironment, autophagy, and ferroptosis.
Conclusions:
This study offers a thorough overview of the most important research topics and emerging trends related to drug resistance and lung cancer immunotherapy. By integrating current knowledge, it enables researchers to swiftly identify pivotal research directions, thereby promoting in-depth development and innovation within the field and supporting the progression of clinical practice. For clinicians, this bibliometric insight provides a more scientific and precise basis for formulating treatment strategies, ultimately assisting lung cancer patients in deriving benefits from immunotherapy.
Insights
This bibliometric analysis reveals key research trends in lung cancer immunotherapy drug resistance, highlighting a shift towards understanding molecular mechanisms like the tumor microenvironment. The findings aid researchers and clinicians in advancing treatment strategies for better patient outcomes.
Area of Science:
- Oncology
- Immunology
- Bibliometrics
Background:
- Lung cancer is a leading cause of cancer death globally.
- Immunotherapy improves survival but faces resistance challenges.
- A comprehensive bibliometric analysis of lung cancer immunotherapy drug resistance is currently lacking.
Purpose of the Study:
- To conduct a bibliometric analysis of lung cancer immunotherapy drug resistance.
- To illuminate the knowledge structure and identify research hotspots in this field.
Main Methods:
- Publications from Web of Science and PubMed (2014-2024) were analyzed.
- Data was processed using NoteExpress, VOSviewer, CiteSpace, and R's 'bibliometrix' package.
- Analysis focused on publication trends, country, institution, and keyword evolution.
Main Results:
- Publication output shows an upward trend, peaking in 2024.
- China leads in publications; the USA has a higher citation impact.
- Keywords evolved from clinical trials and drugs to immune checkpoints (PD-1/PD-L1) and molecular mechanisms (tumor microenvironment, autophagy, ferroptosis).
Conclusions:
- This study provides an overview of research topics and emerging trends in lung cancer immunotherapy drug resistance.
- It helps researchers identify pivotal directions and supports clinical practice by informing treatment strategies.
- Insights facilitate better patient outcomes by optimizing immunotherapy application.
Related Concept Videos
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...